MaxCyte, Inc
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family. It sells instruments, single-use processing assemblies and consumables, and licenses its platform to cell therapy developers through strategic partnership license (SPL) agreements that can also generate milestone and sales-based payments.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCapital equipment sold to cell therapy, biotech and research customers for cell engineering workflows.
Single-use PAs, buffers, accessories and other recurring consumables used with ExPERT instruments.
Research, clinical and SPL license agreements that provide access to the platform and related rights.
Milestone and sales-based payments under SPL partnerships tied to partner clinical and regulatory progress.
Assay services and other smaller platform-related revenue streams.
Products
Reported · share of revenue- Products89.2 %
- Assay and Other Service Revenue9.4 %
- License1.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
MaxCyte sells to cell therapy developers, biopharmaceutical companies, and translational research institutions that need non-viral cell engineering tools. Its customer base includes 29 SPL partners, a majority of the top 25 global pharmaceutical companies, hundreds of biotech companies, and academic and government research centers such as the NIH.
Buy instruments, PAs and licenses to engineer cells for preclinical, clinical and commercial programs.
Use the platform through licenses and partnerships to support internal cell therapy pipelines.
Purchase instruments and consumables for translational research and advancing pipeline programs.
Use the platform for discovery and translational research, supporting installed base growth.
Strategic partners that generate milestone, annual license and sales-based payments as programs progress.
Strategy
MaxCyte is focused on expanding adoption of its non-viral cell engineering platform as cell therapy moves from discovery into clinical development and commercialization. Management is prioritizing sales and marketing, R&D, and product expansion while growing the installed base and increasing the share of customers under SPL agreements.
More SPL agreements can increase recurring license income and milestone opportunities as partner programs mature.
Recurring use of PAs and consumables improves revenue durability versus one-time instrument sales.
The shift away from viral approaches expands the addressable market for Flow Electroporation.
Geography
Q2/2026The company is headquartered in the United States and the disclosed excerpts do not provide a country revenue split. Its business is global in nature because its customer base includes U.S. and foreign biopharma, biotech, academic and government institutions, and its patent portfolio and SPL partnerships extend across major life-science markets.
Share of the revenue the company reports by geography.
Risks
Revenue is inherently lumpy because instrument sales, licenses and SPL milestones depend on customer program timing and clinical/regulatory progress. The company also remains loss-making and cash-burning, so execution on growth, product adoption and capital discipline matters for funding needs and valuation.
SPL milestone and sales-based payments depend on partner achievements that are outside the company's control.
Exposure: Program-related revenue
Instrument, PA and license demand rises only as customers move programs into later-stage development.
Exposure: Core revenue
The company expects near-term operating losses while investing in growth, which can require additional capital over time.
Exposure: Corporate funding
Cell therapy customers may choose competing non-viral or viral workflows if performance, cost or validation is better.
Exposure: Platform adoption
Accounting
Judgemental itemsMilestone and sales-based payments are recognized based on contractual achievement and can shift revenue between periods.
Impact: Drives quarter-to-quarter volatility in program-related revenue
Management tests goodwill using assumptions about growth, margins and discount rates; adverse changes could trigger charges.
Impact: Could create non-cash impairment expense
The SeQure acquisition required fair value estimates for developed technology and goodwill.
Impact: Affects intangible asset balances and future amortization
Future revenue, margins and market conditions influence asset valuations and expense recognition.
Impact: Can materially affect reported earnings and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
PharmaCyte Biotech, Inc.
PMCB · Biological Products, (No Diagnostic Substances)
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Maximus, Inc
MMS · Services-Business Services, NEC
MAXIMUS is a U.S.-based government services contractor that designs and operates tech-enabled programs for federal, state, local, and international public agencies.
Mesoblast Limited
MESO · Biological Products, (No Diagnostic Substances)
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells.
Last updated: 24/09/2026